Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
COVID-19 and androgen-targeted therapy for prostate cancer patients59
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms59
Redifferentiation of radioiodine-refractory thyroid cancers54
Neuroendocrine neoplasm update: toward universal nomenclature49
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms47
Androgen hazards with COVID-1945
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading38
Molecular profiling for acromegaly treatment: a validation study37
The tumor microenvironment and immune responses in prostate cancer patients35
Squamous cell carcinoma of thyroid: a unique type of cancer in World Health Organization Classification35
Therapy considerations in neuroendocrine prostate cancer: what next?34
The role of vitamin D in breast cancer risk and progression34
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature33
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?31
Thyroid cancer in the age of COVID-1931
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas30
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop30
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns30
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy28
Redifferentiation-facilitated radioiodine therapy in thyroid cancer27
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer26
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)26
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues25
Molecular alterations in Hürthle cell nodules and preoperative cancer risk25
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment23
GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours23
Antiangiogenic therapies for pheochromocytoma and paraganglioma23
Genetic profile of advanced thyroid cancers in relation to distant metastasis22
New therapeutic opportunities for women with low-grade serous ovarian cancer22
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?22
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches22
Extrapulmonary poorly differentiated NECs, including molecular and immune aspects22
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review21
Genotype of CDC73 germline mutation determines risk of parathyroid cancer21
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas21
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma21
The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience20
Genomic classification of benign adrenocortical lesions19
Management changes for patients with endocrine-related cancers in the COVID-19 pandemic19
Novel insights in cell cycle dysregulation during prostate cancer progression19
Androgen receptor mutations for precision medicine in prostate cancer18
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer18
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway18
Fibroblast growth factors signaling in bone metastasis18
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers17
Risk factors for intraoperative complications in pheochromocytomas17
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism17
Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison17
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer17
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer16
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes16
Tailoring the approach to radioactive iodine treatment in thyroid cancer16
Genome-wide crosstalk between steroid receptors in breast and prostate cancers16
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives15
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians15
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC15
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors15
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets14
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism14
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET14
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC14
CRISP3 expression drives prostate cancer invasion and progression14
Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress14
A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats14
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine14
Targeted genomic analysis of 364 adrenocortical carcinomas14
Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia14
Critical appraisal of MGMT in digestive NET treated with alkylating agents14
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging13
Gene expression profile in metastatic and non-metastatic parathyroid carcinoma13
Fishing for neuroendocrine tumors13
Molecular connections between circadian rhythm and genome maintenance pathways13
The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors13
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment13
Changing biological behaviour of NETs during the evolution of the disease: progress on progression13
Metastatic medullary thyroid carcinoma: a new way forward12
The thyroid risk score (TRS) for nodules with indeterminate cytology12
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs12
Adiponectin receptor activation inhibits prostate cancer xenograft growth12
Translating the immune microenvironment of thyroid cancer into clinical practice12
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview12
TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?12
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro12
The role of extracellular vesicles in prostate cancer with clinical applications12
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures12
Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer11
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers11
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis11
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs11
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis10
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy10
Leptin-elicited PBX3 confers letrozole resistance in breast cancer10
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives10
Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion10
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)10
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis10
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings10
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma10
Thyroid status regulates the tumor microenvironment delineating breast cancer fate10
Exploring stem cell biology in pituitary tumors and derived organoids10
The role of membrane mucin MUC4 in breast cancer metastasis10
New drug delivery strategies targeting the GnRH receptor in breast and other cancers10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review10
0.021559000015259